By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427


BioMarin leads the biotechnology industry in delivering therapies for chronic and degenerative genetic conditions that reduce patients' quality of life and shorten life spans. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. BioMarin continues to focus on advancing therapies that are the first or best of their kind and make a big difference in improving patients' lives.

BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.

BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates.

You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.

Key Statistics

Ownership: Public

Web Site: BioMarin
Employees: 358
Symbol: BMRN

Company News
A Look at BioMarin (BMRN)'s Potential Blockbuster and the Science Behind It All 10/21/2016 7:30:49 AM
Swinging at Wild Pitches, BioMarin (BMRN) Considering Appealing DMD Drug Rejection 10/14/2016 6:42:37 AM
Why Incyte (INCY), Biogen (BIIB) and BioMarin (BMRN) are Hot Acquisition Targets 10/12/2016 6:02:21 AM
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too 9/23/2016 7:40:10 AM
Sarepta (SRPT) Announces Favorable USPTO Decisions In Exon 51 And Exon 53 Composition Of Matter Patent Interference Cases Against BioMarin (BMRN) 9/21/2016 9:25:45 AM
Rumors Again Swirl Over BioMarin (BMRN) Being a Possible Plan B for Sanofi (SNY) 8/22/2016 9:43:47 AM
Shire (SHPG) Kills Baxalta (BXLT)'s Hemophilia B Program; Clears Path for BioMarin (BMRN), Spark Therapeutics (ONCE) and uniQure (QURE) 8/3/2016 7:26:00 AM
How BioMarin (BMRN)'s Model for Super-Rare Diseases Made It a $15 Billion Powerhouse 7/29/2016 6:37:51 AM
BioMarin (BMRN)'s Gene Therapy Yields Dramatic Results in Early Stage Hemophilia Study 7/28/2016 6:27:39 AM
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines 7/14/2016 6:31:45 AM